Return to homepagePandemic Pact

A phase II investigator-initiated study to evaluate the efficacy and safety of PAI-1 inhibitor TM5614 in patients with SARS-CoV-2 pneumonia

  • Funded by Japan Agency for Medical Research and Development (AMED)
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2020

  • Funder

    Japan Agency for Medical Research and Development (AMED)

  • Principal Investigator

    Professor Hideo HARIGAE

  • Research Location

    Japan

  • Lead Research Institution

    Graduate School of Medicine, Tohoku Universi

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Phase 2 clinical trial

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase II

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract